Bösch, Florian http://orcid.org/0000-0002-0250-9017
Bazhin, Alexandr V.
Heublein, Sabine
Brüwer, Katharina
Knösel, Thomas
Reiter, Florian P.
Auernhammer, Christoph J.
Guba, Markus O.
Spitzweg, Christine
Werner, Jens
Angele, Martin K.
Funding for this research was provided by:
Novartis Pharma (1)
Article History
Received: 27 September 2018
Accepted: 5 June 2019
First Online: 13 June 2019
Ethics approval and consent to participate
: This study was carried out according to the recommendations of the ethics committee of the Medical Faculty of the Ludwig-Maximilians-University Munich, Germany. The ethics committee approved the protocol of the study (no. 15–275). The current study has been performed in a retrospective manner in a cohort of patients diagnosed and treated according to national guidelines. In addition, the data set as well as the specimens were irreversibly anonymized prior to inclusion in the study. Hence, under the circumstances aforementioned a written consent was not necessary. The study was performed according to the standards set in the declaration of Helsinki 1975. All researchers were blinded from patient data during experimental analysis.
: Not Applicable.
: C J A has received research contracts (Ipsen, Novartis), lecture honorarium (Ipsen, Novartis, Pfizer, Falk) and advisory board honorarium (Novartis). The authors declare that they have no competing interests.